BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 593.02 | 0.00 |
| FCF Yield | -0.44% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -2.14 | -3.23 | -59,313.99 | -4,815.35 |
| Quality | ||||
| ROIC | -41.63% | -992,506.90% | -16.58% | -233.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.10 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | -0.00 | -12.25 | -0.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |